<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04284254</url>
  </required_header>
  <id_info>
    <org_study_id>2018LS094</org_study_id>
    <secondary_id>MT2018-18</secondary_id>
    <nct_id>NCT04284254</nct_id>
  </id_info>
  <brief_title>MT2018-18: Sleeping Beauty Transposon-Engineered Plasmablasts for Hurler Syndrome Post Allo HSCT</brief_title>
  <official_title>Sleeping Beauty Transposon-Engineered Plasmablasts for Expression and Delivery of Alpha-L-iduronidase in Patients With Hurler Syndrome That Have Previously Undergone Allogeneic Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, Phase 1/2 study in which patients with Hurler syndrome who have
      previously undergone allogeneic hematopoietic stem cell transplantation are treated with
      autologous plasmablasts engineered to express α-L-iduronidase (IDUA) using the Sleeping
      Beauty transposon system.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>1 Year</time_frame>
    <description>Maximum tolerated dose (MTD) of autologous plasmablasts engineered to express large amounts of α-L-iduronidase (IDUA) using a Sleeping Beauty transposon approach</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Growth Velocity (cm/year)</measure>
    <time_frame>1 Year</time_frame>
    <description>Growth velocity in centimeters/year over a one-year period through determinations of sitting and standing height at baseline and post infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability after Infusion: Incidence of Adverse Events</measure>
    <time_frame>1 Year</time_frame>
    <description>Incidence of Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Z-score Growth Rate</measure>
    <time_frame>1 Year</time_frame>
    <description>Estimate the 1-year Z-score growth rate standardized for age and gender</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Engraftment</measure>
    <time_frame>Baseline, 6 months and 1 Year</time_frame>
    <description>Estimate percent myeloid donor chimerism (CD33/66b) at baseline and at 6 and 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of circulating antibodies (IgG, IgM, IgA and IgE)</measure>
    <time_frame>1 Year</time_frame>
    <description>Determine levels of circulating antibodies (IgG, IgM, IgA and IgE) at baseline and at scheduled time points post infusion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Mucopolysaccharidosis Type IH (MPS IH, Hurler Syndrome)</condition>
  <condition>Mucopolysaccharidosis Type IH</condition>
  <condition>MPS IH, Hurler Syndrome</condition>
  <arm_group>
    <arm_group_label>Phase 1: Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 - Expansion at MTD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Autologous Plasmablasts</intervention_name>
    <description>Autologous Plasmablasts engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty transposon system.
Phase 1:
Dose Level 1: 5 x 10e7 cells/kg on Day 0
Dose Level 2: 1 x 10e8 cells/kg on Day 0
Dose Level 3: 1 x 10e8 cells/kg x 2 doses on Day 0 and Day 30 +/-3 days.
Phase 2:
- Maximum Tolerated Dose (MTD) established in Phase I</description>
    <arm_group_label>Phase 1: Dose Escalation</arm_group_label>
    <arm_group_label>Phase 2 - Expansion at MTD</arm_group_label>
    <other_name>Sleeping Beauty</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Mucopolysaccharidosis type IH (MPS IH, Hurler syndrome)

          -  Underwent a previous hematopoietic stem cell transplant &gt;1 year prior to study
             enrollment

          -  Age ≥3 years and ≤8 years at time of study registration

          -  ≥ 10 kilograms body weight

          -  Creatinine &lt;1.5 normal for gender and age.

          -  Ejection fraction ≥ 40% by echocardiogram

          -  Must commit to traveling to the University of Minnesota for the necessary followup
             evaluations

          -  Must agree to stay in the Twin Cities area (&lt;45-minute drive from the Masonic
             Children's Hospital) for a minimum of 5 days after each cell infusion

          -  Voluntary written parental consent prior to the performance of any study related
             procedures

        Exclusion Criteria:

          -  Prior enzyme replacement therapy within 4 months prior to enrolling on study

          -  History of B cell related cancer, EBV lymphoproliferative disease or autoimmune
             disorders

          -  Evidence of active graft vs. host disease

          -  Requirement for systemic immune suppression

          -  Requirement for continuous supplemental oxygen

          -  Any medical condition likely to interfere with assessment of safety or efficacy of the
             study treatment.

          -  In the investigator's judgement, the subject is unlikely to complete all protocol
             required study visits or procedures, including follow up visits, or comply with the
             study requirements for participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Orchard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota, Department of Pediatrics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Orchard, MD</last_name>
    <phone>(612)-626-2313</phone>
    <email>orcha001@umn.edu</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MPS IH</keyword>
  <keyword>Hurler syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

